日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia

STAT3降解剂在维奈托克耐药的急性髓系白血病中显示出疗效

Chakraborty, Samarpana; Morganti, Claudia; Zaldana, Kimberly; Rivera Pena, Bianca; Zhang, Hui; Verma, Divij; Gitego, Nadege; Ma, Feiyang; Aluri, Srinivas; Pradhan, Kith; Gordon-Mitchell, Shanisha; Mantzaris, Ioannis; Goldfinger, Mendel; Feldman, Eric; Gritsman, Kira; Shi, Yang; Hubner, Stefan; Qiu, Yi Hua; Brown, Brandon D; Khasawneh, Abdullah; Skwarska, Anna; de Camargo Magalhães, Eduardo Sabino; Verma, Amit; Konopleva, Marina; Tabe, Yoko; Gavathiotis, Evripidis; Colla, Simona; Gollob, Jared; Dey, Joyoti; Kornblau, Steven M; Koralov, Sergei B; Ito, Keisuke; Shastri, Aditi

Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia

地西他滨和维奈托克的节拍式低剂量方案安全有效,并能降低慢性粒单核细胞白血病中的单核细胞负荷。

Rockwell, Bradley; Goldfinger, Mendel; Mantzaris, Ioannis; Shastri, Aditi; Saunthararajah, Yogen; Gritsman, Kira; Sica, Alejandro R; Kornblum, Noah; Shah, Nishi; Levitz, David; Shapiro, Lauren C; Gupta, Ridhi; Munoz, Anne; Dhawan, Aradhika; Fehn, Karen; Comas, Monica; Verceles, Jhannine; Cooper, Dennis L; Konopleva, Marina; Feldman, Eric J; Verma, Amit

The LSC17 score: a prognostic biomarker now validated for real-world clinical application in acute myeloid leukemia

LSC17评分:一种预后生物标志物,现已验证可用于急性髓系白血病的真实世界临床应用

Sandhu, Michael; Konopleva, Marina

Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor

一线去甲基化药物维奈托克联合FLT3抑制剂治疗FLT3突变型急性髓系白血病患者的长期疗效

Short, Nicholas J; Loghavi, Sanam; Yilmaz, Musa; Karrar, Omer; Kim, Kunhwa; Dinardo, Courtney D; Kadia, Tapan M; Maroun, Manuel; Borthakur, Gautam; Issa, Ghayas C; Jabbour, Joseph; Oran, Betul; Shpall, Elizabeth J; Popat, Uday; Patel, Keyur P; Routbort, Mark; Konopleva, Marina; Ravandi, Farhad; Kantarjian, Hagop; Daver, Naval

Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study

血液系统恶性肿瘤疗法(包括细胞疗法)的经济毒性及其对医疗服务可及性的影响:前瞻性试点研究

Amaeshi, Lemchukwu; Laufer, Lauren; Fedorov, Kateryna; Sisto, Alex; Levitz, David; Mathew, Rosmi; Wright, Karen; Cooper, Dennis; Goldfinger, Mendel; Mantzaris, Ioannis; Sica, R Alejandro; Gritsman, Kira; Konopleva, Marina; Gupta, Ridhi; Kornblum, Noah; Zhang, Chenxin; Kim, Mimi; Verma, Amit; Rapkin, Bruce; Shastri, Aditi; Shah, Nishi

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML

对于不适合接受强化化疗的异柠檬酸脱氢酶突变型急性髓系白血病患者,一线三联疗法(包括去甲基化药物、维奈托克和异柠檬酸脱氢酶抑制剂)的疗效

DiNardo, Courtney D; Marvin-Peek, Jennifer; Loghavi, Sanam; Takahashi, Koichi; Issa, Ghayas C; Jen, Wei-Ying; Daver, Naval G; Reville, Patrick K; Short, Nicholas J; Sasaki, Koji; Mullin, Jillian K; Bradley, Corey A; Borthakur, Gautam; Maiti, Abhishek; Alvarado, Yesid; Pemmaraju, Naveen; Abbas, Hussein A; Hammond, Danielle E; Haddad, Fadi; Bravo, Guillermo Montalban; Chien, Kelly S; Yilmaz, Musa; Kornblau, Steven M; Jabbour, Elias; Ravandi, Farhad; Kadia, Tapan; Garcia-Manero, Guillermo; Konopleva, Marina Y; Kantarjian, Hagop M

A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias

DS-1594 menin抑制剂治疗复发/难治性急性白血病的1/2期研究

Senapati, Jayastu; Konopleva, Marina; Issa, Ghayas C; Jabbour, Elias; Kadia, Tapan; DiNardo, Courtney; Borthakur, Gautam; Pemmaraju, Naveen; Short, Nicholas J; Yilmaz, Musa; Deshmukh, Indraneel; Alvarez, Joie; Loghavi, Sanam; Tang, Guilin; Abbas, Hussein A; Andreeff, Michael; Bhalla, Kapil; Midde, Narasimha M; Said, Nabil; Noyalis, Amy; Mires, Derek E; Ning, Jing; Xiao, Lianchun; Ravandi, Farhad; Garcia-Manero, Guillermo; Kantarjian, Hagop M; Daver, Naval G

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML

新型 BCL-xL 降解剂 DT2216 在 JAK2 突变型 MPN 后 AML 临床前模型中的疗效

Wang, Zhe; Skwarska, Anna; Poigaialwar, Gowri; Chaudhry, Sovira; Rodriguez-Meira, Alba; Sui, Pinpin; Olivier, Emmanuel; Jia, Yannan; Gupta, Varun; Fiskus, Warren; Ramage, Cassandra L; Zheng, Guangrong; Schurer, Alexandra; Gritsman, Kira; Papapetrou, Eirini P; Bhalla, Kapil; Zhou, Daohong; Mead, Adam J; Rampal, Raajit K; Tyner, Jeffrey W; Abbas, Hussein A; Pemmaraju, Naveen; Tatarata, Qi Zhang; Konopleva, Marina

Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia

Venetoclax联合gilteritinib在FLT3突变型BCL11B-a谱系不明确白血病的临床前模型中有效。

Lindsey E Montefiori,Ilaria Iacobucci,Qingsong Gao,Jamila Moore,William C Wright,Huimei Wei,Pradyumna Baviskar,Surbhi Sona,Hongjian Jin,Amit Budhraja,Josi Lott,Qi Zhang Tatarata,Zhongshan Cheng,Tanya Khan,Emily A Backhaus Wagner,Melissa Johnson,Cyrus M Mehr,Burgess Freeman,Laura Janke,Torsten Haferlach,Paul Geeleher,Paul E Mead,Marina Konopleva,Joseph T Opferman,Charles G Mullighan

DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia

DNTT介导的DNA损伤反应驱动B细胞急性淋巴细胞白血病对inotuzumab ozogamicin产生耐药性

Carolin S Escherich ,Takaya Moriyama ,Zhenhua Li ,Yu-Chih Hsiao ,Wenjian Yang ,Yizhen Li ,Noemi Reyes ,Megan Walker ,Amit Budhraja ,Sheetal Bhatara ,Ernesto Diaz-Flores ,Wendy Stock ,Elisabeth Paietta ,Marina Y Konopleva ,Steven M Kornblau ,Mark R Litzow ,Hiroto Inaba ,Ching-Hon Pui ,Joseph T Opferman ,Mignon L Loh ,Jiyang Yu ,Maureen M O'Brien ,William E Evans ,Jun J Yang